ClinicalTrials.gg
RecruitingNCT07523880Updated Apr 13, 2026

Multi-Omics-Based Novel Thrombosis and Bleeding Markers and Risk Model for CHD

An observational study in Thrombosis, Bleeding and Coronary Artery Disease (CAD), sponsored by Xueyan Zhao. Recruiting at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Xueyan Zhao · Observational

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
12,154
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 67 studies in Thrombosis with a site in China — 18 open to participants now, 20 under way, none of them phase 3. Thrombosis · China.

Planned enrollment
Largest of 26
12,154 · median 500
Started
2025
with 3 others
Observational
26 of 67
15 open now
Primary completion
2029-01
later than 16 of 19 live
Registered
61st of 67
by date

Among the 67 studies in Thrombosis with a site in China, this one has the largest planned enrollment of the 26 observational ones that give a count, is one of 4 that started in 2025, is one of 26 observational ones, reaches primary completion later than 16 of the 19 other live ones, and was the 61st registered.

Thrombosis

956 studies on the registry are indexed under Thrombosis; 172 are open to participants now.

Browse Thrombosis studies →

Open to participants now

18 of the 67 studies in Thrombosis with a site in China are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 128 Thrombosis studies recruiting now, 80 (63%) set no upper age limit and 17 (13%) stop at 75 or younger; 21 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Thrombosis with a site in China, or all of them as a file.
02

Study summary

Patients with coronary heart disease who take dual antiplatelet therapy face two serious risks: thrombosis and major bleeding. This study aims to develop better ways to predict these risks and guide personalized treatment.

The investigators will use a large, long-term follow-up study of Chinese patients with coronary heart disease. This research plans to discover new biomarkers related to clot and bleeding risk. The study will combine information from proteins, metabolites, sugars attached to proteins, genes, and medical images. Using machine learning methods, the investigators will identify the most important markers and test them in the patient group of this study.

The investigators will then build new risk prediction models that include these new markers together with traditional risk scores (such as GRACE, PARIS, and Precise-DAPT). This study will check whether these new models are better than existing ones at predicting who will develop clots or bleeding and at helping doctors decide on the best treatment for each patient.

The new aspects of this research are: (1) using advanced multi-omics technology to find novel markers specifically for Chinese patients; (2) combining clinical, biological, and imaging data to improve prediction accuracy; and (3) using machine learning to create more precise risk models.

The goal is to provide doctors with a more accurate tool to assess each patient's risk of clots and bleeding. This will help them choose the safest and most effective antiplatelet treatment, reduce serious complications, and improve patient care.

03

Conditions studied

  • Thrombosis
  • Bleeding
  • Coronary Artery Disease (CAD)

Keywords

  • Coronary Heart Disease
  • Dual Antiplatelet Therapy
  • Thrombosis
  • Bleeding
  • Multi-Omics
  • Biomarkers
  • Risk Prediction Model
  • Machine Learning
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of patients with coronary heart disease who are receiving dual antiplatelet therapy after percutaneous coronary intervention. The study includes a retrospective cohort of approximately 10,154 patients with existing baseline and follow-up data and biospecimens, derived from a previously established patient cohort. In addition, a prospective cohort of at least 2,000 newly enrolled patients will be recruited.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years.
  2. Hospitalized due to symptoms or objective evidence of coronary heart disease and planned for long-term antithrombotic therapy.
  3. Diagnosis of acute coronary syndrome or stable coronary heart disease undergoing percutaneous coronary intervention (PCI), with clinical stability meeting discharge criteria after treatment.
  4. For patients from the existing cohort: minimum 2 years of follow-up with complete clinical data and blood specimens available; approval for use of these data and specimens has been obtained, with a waiver of re-consent.

For newly enrolled patients: voluntary written provided by the patient or legal representative, agreement to provide blood samples, and acceptance of follow-up procedures.

Exclusion criteria

Exclusion Criteria:

For patients from the existing cohort:

  1. Severe missing or erroneous baseline or clinical data that cannot be corrected by source verification.
  2. No available blood specimen, or specimen that does not meet testing requirements.

For newly enrolled patients:

  1. Presence of serious comorbid conditions with ≤ 6 months.
  2. Conditions that significantly affect study compliance or the ability to complete follow-up.
  3. to blood sampling.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
12,154 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Retrospective Cohort

    Approximately 10,154 patients with coronary heart disease selected from an established cohort of 18,701 patients based on inclusion/exclusion criteria.

  • Prospective Cohort

    At least 2,000 newly enrolled patients with coronary heart disease. Participants will be followed prospectively for thrombotic and bleeding events.

06

What researchers measure

Primary outcomes

  1. Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)

    Composite of all-cause death, non-fatal myocardial infarction, ischemic stroke, and unplanned revascularization.

    Time frame: Up to 24 months after enrollment

  2. Major Bleeding Events

    Bleeding Academic Research Consortium (BARC) type 3 or type 5 bleeding.

    Time frame: Up to 24 months after enrollment

Secondary outcomes

  1. All-Cause Death

    Time frame: Up to 24 months after enrollment

  2. Myocardial Infarction

    Time frame: Up to 24 months after enrollment

  3. Stroke

    Time frame: Up to 24 months after enrollment

  4. Stent Thrombosis

    Time frame: Up to 24 months after enrollment

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jan 2029, 41 months after the start.

Of 160 non-industry observational studies under Thrombosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 114. This study's planned 41 months is close to that.

Counting every sponsor, half of 189 studies reached it within 31 months; a quarter within 12 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2026
First posted
Apr 13, 2026
StartActual
Aug 1, 2025
Primary completionEst.
Jan 2029
CompletionEst.
Jul 2029
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07523880
Lead sponsor
Xueyan Zhao
Collaborators
The General Hospital of Northern Theater Command, Central China Fuwai Hospital of Zhengzhou University
Responsible party
Xueyan Zhao (Chief Physician, Chinese Academy of Medical Sciences, Fuwai Hospital) — Sponsor-investigator
First posted
Apr 13, 2026
Start date
Aug 1, 2025
Primary completion
Jan 2029 (estimated)
Completion
Jul 2029 (estimated)
Last update
Apr 13, 2026

Study contacts

Xueyan Zhao, PhD
Contact
zhao_xueyan@sina.com
+86 13683185878

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion